Latest Pancreatin Stories
Tokyo, Aug 29, 2011 - (JCN Newswire) - Abbott Japan Co., Ltd. and Eisai Co., Ltd.
ABBOTT PARK, Ill., June 14, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved an infant-specific dose of CREON(R) (pancrelipase) Delayed-Release Capsules to treat exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF).
INDIANAPOLIS and CAMBRIDGE, Mass., July 2 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) and Alnara Pharmaceuticals, Inc.
ABBOTT PARK, Ill.., May 3 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced that the U.S.
MARIETTA, Ga., July 7 /PRNewswire/ -- Solvay Pharmaceuticals, Inc. today announced the commercial availability of CREON(R) (pancrelipase) Delayed-Release Capsules.
US-based pharmaceutical company Digestive Care has completed the submission of the new drug application for Pancrecarb, used in the treatment of exocrine pancreatic insufficiency, to the FDA.
By Hauenschild, Annette Ewald, Nils; Klauke, Thorsten; Liebchen, Ariane; Bretzel, Reinhard Georg; Kloer, Hans-Ulrich; Hardt, Philip Daniel ABSTRACT.